Clinical Trial Insights
Welcome to Cytel’s Insights hub—your go-to destination for the latest news, event updates, and expert insights on advanced analytical methods and data science. Come on in!
Unlock the Path to Successful EU JCA Submissions
Your Essential Guide to Navigating the New Era of Joint Clinical Assessments
The European Union’s Joint Clinical Assessment (JCA) is transforming how clinical effectiveness is evaluated across Member States, ushering in a unified, more efficient approach to health technology assessments. Our latest eBook, “Unlock the Path to Successful EU JCA Submissions,” is a must-read for pharmaceutical companies and technology developers aiming to stay ahead in this evolving regulatory landscape.
With expert insights and actionable strategies, this comprehensive guide empowers you to align your clinical, regulatory, and market access efforts for optimal success under the new EU JCA framework.
Read morePerspectives
Our experts share cutting-edge insights, industry trends, and in-depth analyses spanning the full spectrum of drug lifecycle management, from initial development through to successful commercialization.
Real-World Evidence as a Success Factor in AMNOG Dossiers: Deriving Robust Target Populations Using Claims Data and FDZ Analyses
The FDA Revises Master Protocol Guidance: What Drug Developers Should Know
Blinded and Unblinded Statistical Roles in Clinical Trials
It Got Worse Than Expected: Lessons from Three Years of FDA CBER Requests on SDTM, ADaM, and TFLs
News and Events
Stay up to date with the latest news and events here at Cytel and beyond. We will inform you about the upcoming industry events, our participation and contribution, keeping you connected and in the know.
Panel Discussion – Closing the Women’s Health Gap Through Better Data & Sex-Sensitive Analyses
Webinar – Rethinking Evidence, Value, and Access: From Artificial Intelligence to Living HTA
Office Hours – Beyond Spreadsheets: Using R Shiny to Bring Health Economic Value to Life
Resource Library
The Cytel Library is always open—explore our extensive collection of articles, white papers, case studies, and more to discover how we are shaping the future of drug development.
Publications
Stay up to date with our latest peer-reviewed publications on our Cytel pubmed page.
Patient characteristics, burden of disease, healthcare resource utilization and costs in acute myeloid leukemia – a retrospective observational study with German claims data. Greth, K., Lehne, M., Ghiani, M., Mevius, A., Purcell, S., Kaulfuss, S., Gokhale, M., & Russell, A. (2026). Journal of comparative effectiveness research, 15(1), e240196.
Effect of tezepelumab on asthma exacerbations co-occurring with infection-attributed acute respiratory illnesses. Feleszko, W., Caminati, M., Gern, J. E., Johnston, S. L., Marchese, C., Clarke, D., Ambrose, C. S., & Lindsley, A. W. (2026). Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 136(1), 61–65.e1.
Graph Based, Adaptive, Multiarm, Multiple Endpoint, Two-Stage Designs. Mehta, C., Mukhopadhyay, A., & Posch, M. (2025). Statistics in medicine, 44(28-30), e70237
Intersectoral action to transform health equity for women and girls globally. Sarri, G., Soriano Gabarró, M. S., Cheng, R. F., & Jhutti-Johal, J. (2025). Communications medicine, 6(1), 40.
Claim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug’s probability of success and plot a clearer route to market.
